Tag: ipilimumab

What is Ipilimumab? Ipilimumab is a humanized monoclonal antibody that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a key immune checkpoint receptor that downregulates immune activation. By blocking CTLA-4, ipilimumab enhances T-cell activation and proliferation, promoting an immune response against cancer cells. It is primarily used in combination with nivolumab (anti-PD-1 antibody) for treating various advanced…